SG11201908065YA - Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer - Google Patents
Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancerInfo
- Publication number
- SG11201908065YA SG11201908065YA SG11201908065YA SG11201908065YA SG11201908065YA SG 11201908065Y A SG11201908065Y A SG 11201908065YA SG 11201908065Y A SG11201908065Y A SG 11201908065YA SG 11201908065Y A SG11201908065Y A SG 11201908065YA SG 11201908065Y A SG11201908065Y A SG 11201908065YA
- Authority
- SG
- Singapore
- Prior art keywords
- compounds
- international
- cambridge
- astrazeneca
- quinolin
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- NSHFLKZNBPJNPA-UHFFFAOYSA-N imidazo[4,5-c]quinolin-2-one Chemical class C1=CC=C2C3=NC(=O)N=C3C=NC2=C1 NSHFLKZNBPJNPA-UHFFFAOYSA-N 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 241000656145 Thyrsites atun Species 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000002402 nanowire electron scattering Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472080P | 2017-03-16 | 2017-03-16 | |
| PCT/EP2018/056516 WO2018167203A1 (fr) | 2017-03-16 | 2018-03-15 | Composés imidazo[4,5-c]quinolin-2-one deutérés et leur utilisation dans le traitement du cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908065YA true SG11201908065YA (en) | 2019-09-27 |
Family
ID=61801891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908065YA SG11201908065YA (en) | 2017-03-16 | 2018-03-15 | Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20200087300A1 (fr) |
| EP (1) | EP3596076A1 (fr) |
| JP (1) | JP2020514344A (fr) |
| KR (1) | KR20190129923A (fr) |
| CN (1) | CN110431139B (fr) |
| AU (1) | AU2018234985B2 (fr) |
| BR (1) | BR112019018723A2 (fr) |
| CA (1) | CA3055258A1 (fr) |
| CL (1) | CL2019002527A1 (fr) |
| CO (1) | CO2019010029A2 (fr) |
| CR (1) | CR20190429A (fr) |
| DO (1) | DOP2019000228A (fr) |
| EA (1) | EA038233B1 (fr) |
| EC (1) | ECSP19066134A (fr) |
| IL (1) | IL269272A (fr) |
| JO (1) | JOP20190209A1 (fr) |
| MA (1) | MA49884A (fr) |
| MX (1) | MX2019010898A (fr) |
| NI (1) | NI201900094A (fr) |
| PE (1) | PE20191486A1 (fr) |
| PH (1) | PH12019502086A1 (fr) |
| SG (1) | SG11201908065YA (fr) |
| TW (1) | TW201843151A (fr) |
| UA (1) | UA124554C2 (fr) |
| WO (1) | WO2018167203A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LV15575A (lv) * | 2019-12-20 | 2021-06-20 | Latvijas Organiskās Sintēzes Institūts | Selenofēnhromēnu deiterēti analogi, to iegūšana un izmantošana |
| US20230256110A1 (en) | 2020-06-24 | 2023-08-17 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and atm inhibitor |
| WO2022060377A1 (fr) * | 2020-09-21 | 2022-03-24 | Wei Zhong | Composés substitués de 1-(3,3-difluoropipéridin-4-yl)-imidazo[4,5-c]quinoléin-2-one présentant une aptitude à traverser la barrière hémato-encéphalique |
| EP3992191A1 (fr) | 2020-11-03 | 2022-05-04 | Deutsches Krebsforschungszentrum | Dérivés d'imidazo[4,5-c]quinoline et leur utilisation en tant qu'inhibiteurs de kinase atm |
| WO2022128833A1 (fr) | 2020-12-15 | 2022-06-23 | Merck Patent Gmbh | Complexes métal-ligand de transition solide |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| ATE237596T1 (de) | 1996-02-13 | 2003-05-15 | Astrazeneca Ab | Chinazolinderivate und deren verwendung als vegf hemmer |
| US6291455B1 (en) | 1996-03-05 | 2001-09-18 | Zeneca Limited | 4-anilinoquinazoline derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| US20090082387A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched nvp-bez234 |
| PE20120224A1 (es) * | 2009-06-04 | 2012-04-04 | Novartis Ag | Derivados de 1h-imidazo-[4,5-c]-quinolinona |
| CN102372711B (zh) * | 2010-08-18 | 2014-09-17 | 山东轩竹医药科技有限公司 | 咪唑并喹啉类PI3K和mTOR双重抑制剂 |
| CN102399218A (zh) * | 2010-09-16 | 2012-04-04 | 和记黄埔医药（上海）有限公司 | 一类并合三杂环及其作为pi3k抑制剂的用途 |
| NO2714752T3 (fr) * | 2014-05-08 | 2018-04-21 | ||
| LT3560924T (lt) * | 2015-04-02 | 2021-08-25 | Merck Patent Gmbh | Imidazolonilchinolinai ir jų panaudojimas kaip atm kinazės inhibitorių |
| GB201516504D0 (en) * | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
-
2017
- 2017-06-16 JO JOP/2019/0209A patent/JOP20190209A1/ar unknown
-
2018
- 2018-03-15 KR KR1020197030079A patent/KR20190129923A/ko not_active Abandoned
- 2018-03-15 CN CN201880017916.4A patent/CN110431139B/zh active Active
- 2018-03-15 EP EP18713818.5A patent/EP3596076A1/fr not_active Withdrawn
- 2018-03-15 SG SG11201908065YA patent/SG11201908065YA/en unknown
- 2018-03-15 UA UAA201910213A patent/UA124554C2/uk unknown
- 2018-03-15 US US16/493,850 patent/US20200087300A1/en not_active Abandoned
- 2018-03-15 MX MX2019010898A patent/MX2019010898A/es unknown
- 2018-03-15 CA CA3055258A patent/CA3055258A1/fr not_active Abandoned
- 2018-03-15 AU AU2018234985A patent/AU2018234985B2/en not_active Ceased
- 2018-03-15 MA MA049884A patent/MA49884A/fr unknown
- 2018-03-15 PE PE2019001872A patent/PE20191486A1/es unknown
- 2018-03-15 TW TW107108833A patent/TW201843151A/zh unknown
- 2018-03-15 EA EA201992090A patent/EA038233B1/ru unknown
- 2018-03-15 WO PCT/EP2018/056516 patent/WO2018167203A1/fr not_active Ceased
- 2018-03-15 CR CR20190429A patent/CR20190429A/es unknown
- 2018-03-15 JP JP2019549446A patent/JP2020514344A/ja not_active Ceased
- 2018-03-15 BR BR112019018723A patent/BR112019018723A2/pt not_active Application Discontinuation
-
2019
- 2019-09-03 CL CL2019002527A patent/CL2019002527A1/es unknown
- 2019-09-06 DO DO2019000228A patent/DOP2019000228A/es unknown
- 2019-09-11 IL IL26927219A patent/IL269272A/en unknown
- 2019-09-12 EC ECSENADI201966134A patent/ECSP19066134A/es unknown
- 2019-09-13 PH PH12019502086A patent/PH12019502086A1/en unknown
- 2019-09-13 NI NI201900094A patent/NI201900094A/es unknown
- 2019-09-16 CO CONC2019/0010029A patent/CO2019010029A2/es unknown
-
2021
- 2021-07-20 US US17/380,323 patent/US20210347775A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CR20190429A (es) | 2019-11-12 |
| CL2019002527A1 (es) | 2019-11-22 |
| MX2019010898A (es) | 2019-11-07 |
| BR112019018723A2 (pt) | 2020-04-07 |
| IL269272A (en) | 2019-11-28 |
| WO2018167203A1 (fr) | 2018-09-20 |
| DOP2019000228A (es) | 2019-09-30 |
| CO2019010029A2 (es) | 2019-09-30 |
| MA49884A (fr) | 2020-06-24 |
| NI201900094A (es) | 2020-03-18 |
| UA124554C2 (uk) | 2021-10-05 |
| AU2018234985B2 (en) | 2020-04-02 |
| EP3596076A1 (fr) | 2020-01-22 |
| KR20190129923A (ko) | 2019-11-20 |
| PH12019502086A1 (en) | 2020-03-09 |
| AU2018234985A1 (en) | 2019-10-24 |
| US20200087300A1 (en) | 2020-03-19 |
| CA3055258A1 (fr) | 2018-09-20 |
| JP2020514344A (ja) | 2020-05-21 |
| TW201843151A (zh) | 2018-12-16 |
| ECSP19066134A (es) | 2019-09-30 |
| EA201992090A1 (ru) | 2020-03-06 |
| JOP20190209A1 (ar) | 2019-09-12 |
| PE20191486A1 (es) | 2019-10-18 |
| US20210347775A1 (en) | 2021-11-11 |
| CN110431139A (zh) | 2019-11-08 |
| EA038233B1 (ru) | 2021-07-28 |
| CN110431139B (zh) | 2022-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201906222WA (en) | Jak1 selective inhibitors | |
| SG11201903182XA (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer | |
| SG11201908065YA (en) | Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201908971RA (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene | |
| SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| SG11202000266VA (en) | Quinoline derivatives for treating infections with helminths | |
| SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201810396QA (en) | Pegylated carfilzomib compounds | |
| SG11201901558VA (en) | Pth compounds with low peak-to-trough ratios | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
| SG11201900486WA (en) | Treatment and prevention of sleep disorders | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201806424TA (en) | Therapeutic compounds | |
| SG11201906767XA (en) | Estrogen receptor modulators | |
| SG11201907505TA (en) | Low-viscosity, high-concentration evolocumab formulations and methods of making the same | |
| SG11201807523PA (en) | Ilt7 binding molecules and methods of using the same | |
| SG11201901249YA (en) | Aza-indazole compounds for use in tendon and/or ligament injuries | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
| SG11201804587QA (en) | Isoindole compounds | |
| SG11201810358YA (en) | Compositions and methods for treating negative symptoms in non-schizophrenic patients | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders |